JP2009534367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534367A5 JP2009534367A5 JP2009505965A JP2009505965A JP2009534367A5 JP 2009534367 A5 JP2009534367 A5 JP 2009534367A5 JP 2009505965 A JP2009505965 A JP 2009505965A JP 2009505965 A JP2009505965 A JP 2009505965A JP 2009534367 A5 JP2009534367 A5 JP 2009534367A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- composition according
- agonist
- functional muscarinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000556 agonist Substances 0.000 claims 11
- 230000003551 muscarinic effect Effects 0.000 claims 11
- 206010001497 Agitation Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 206010012374 Depressed mood Diseases 0.000 claims 5
- 238000013019 agitation Methods 0.000 claims 5
- 208000019116 sleep disease Diseases 0.000 claims 5
- 206010011971 Decreased interest Diseases 0.000 claims 4
- 206010041243 Social avoidant behaviour Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 208000037048 Prodromal Symptoms Diseases 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 230000006866 deterioration Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 230000002536 noncholinergic effect Effects 0.000 claims 2
- 208000022925 sleep disturbance Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0607952.9A GB0607952D0 (en) | 2006-04-21 | 2006-04-21 | Novel treatment |
| PCT/GB2007/001463 WO2007125287A1 (en) | 2006-04-21 | 2007-04-23 | Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009534367A JP2009534367A (ja) | 2009-09-24 |
| JP2009534367A5 true JP2009534367A5 (enExample) | 2010-06-17 |
Family
ID=36581049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505965A Pending JP2009534367A (ja) | 2006-04-21 | 2007-04-23 | 前駆症状症候群の治療にｍ１／ｍ４ムスカリン性アゴニスト（サブコメリン）を用いる単独及び組合せ療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090318414A1 (enExample) |
| EP (1) | EP2012783A1 (enExample) |
| JP (1) | JP2009534367A (enExample) |
| CN (1) | CN101472586A (enExample) |
| CA (1) | CA2649590A1 (enExample) |
| GB (1) | GB0607952D0 (enExample) |
| WO (1) | WO2007125287A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2742728T3 (es) | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| ES2811088T3 (es) | 2014-04-23 | 2021-03-10 | Takeda Pharmaceuticals Co | Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer |
| EP3313836B1 (en) | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| PT3856182T (pt) | 2018-09-28 | 2026-03-10 | Karuna Therapeutics Inc | Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE269330T1 (de) * | 1989-04-13 | 2004-07-15 | Beecham Group Plc | Chemische verbindungen |
| GB0008921D0 (en) * | 2000-04-11 | 2000-05-31 | Smithkline Beecham Plc | Method of treatment |
| US20010036949A1 (en) * | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| CA2410680A1 (en) * | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
| US20040023951A1 (en) * | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| AU2002359875B2 (en) * | 2001-12-28 | 2009-01-08 | Acadia Pharmaceuticals Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| GB0428180D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
-
2006
- 2006-04-21 GB GBGB0607952.9A patent/GB0607952D0/en not_active Ceased
-
2007
- 2007-04-23 CA CA002649590A patent/CA2649590A1/en not_active Abandoned
- 2007-04-23 WO PCT/GB2007/001463 patent/WO2007125287A1/en not_active Ceased
- 2007-04-23 US US12/226,423 patent/US20090318414A1/en not_active Abandoned
- 2007-04-23 CN CNA2007800232331A patent/CN101472586A/zh active Pending
- 2007-04-23 JP JP2009505965A patent/JP2009534367A/ja active Pending
- 2007-04-23 EP EP07732503A patent/EP2012783A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lara et al. | Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression | |
| Malhotra et al. | Nicotine and periodontal tissues | |
| CN101772346B (zh) | 用于降低治疗副作用的方法和组合物 | |
| JP2022180461A5 (enExample) | ||
| JP6099609B2 (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| JP2010525050A5 (enExample) | ||
| WO2018136554A1 (en) | Use of neurokinin-1 antagonists as antitussives | |
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| JP2014528474A5 (enExample) | ||
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| AR065579A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| JP2010522137A5 (enExample) | ||
| SI2501234T1 (en) | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine | |
| PL2043637T3 (pl) | Sposoby i leki do podawania ibuprofenu | |
| JP2013541583A5 (enExample) | ||
| JP2024501919A5 (enExample) | ||
| JP2005508963A5 (enExample) | ||
| JP2019514990A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2011500589A5 (enExample) | ||
| RU2011111792A (ru) | Применение парацетамола и ибупрофена в лечении | |
| JP2008534663A (ja) | 慢性的な痛みおよび疲労を特徴とする症候群の治療のためのネフォパムおよびその類似体の使用 | |
| JP2006508994A5 (enExample) | ||
| CA2506962A1 (en) | Synergistic combination comprising roflumilast and formoterol |